Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

H1637

Sigma-Aldrich

cis-4-Hydroxy-L-proline

collagen synthesis inhibitor

Sinonimo/i:

(2S,4S)-(−)-4-Hydroxy-2-pyrrolidinecarboxylic acid, CHP

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C5H9NO3
Numero CAS:
618-27-9
Peso molecolare:
131.13
Beilstein:
81440
Numero CE:
210-542-1
Numero MDL:
MFCD00064319
Codice UNSPSC:
12352209
eCl@ss:
32160406
ID PubChem:
24895470
NACRES:
NA.26

Livello qualitativo

100

Saggio

≥98% (TLC)

Forma fisica

powder

tecniche

ligand binding assay: suitable

Colore

white to faint yellow

Punto di fusione

257 °C (dec.) (lit.)

applicazioni

peptide synthesis

Stringa SMILE

O[C@@H]1CN[C@@H](C1)C(O)=O

InChI

1S/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4-/m0/s1
PMMYEEVYMWASQN-IMJSIDKUSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Applicazioni

cis-4-Hydroxy-L-proline (CHP) is a proline analog that inhibits collagen synthesis and has been used as an anticancer compound. CHP blocked myotube formation and expression of sarcomeric myosin heavy chain in C2C12 murine skeletal muscle cells. CHP inhibited proliferation of murine Panc02 pancreatic carcinoma cell line and rat pancreatic carcinoma cell line DSL6A.

Azioni biochim/fisiol

cis-4-Hydroxy-L-proline (CHP) and its derivatives may have anticancer activity. cis-4-Hydroxy-L-proline and other hydrosyl-L-prolines are important intermediates for chiral synthesis of potential drugs.

Altre note

Constituent of Amanita sp. peptide toxins but not of animal proteins like collagen.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 3

1 of 3

trans-4-Hydroxy-L-proline analytical standard

Supelco

41875

trans-4-Hydroxy-L-proline

N-Boc-cis-4-hydroxy-L-proline methyl ester 97%

Sigma-Aldrich

654000

N-Boc-cis-4-hydroxy-L-proline methyl ester

Z-Hyp-OH ≥99.0% (T)

Sigma-Aldrich

96310

Z-Hyp-OH

Ryotaro Hara et al.
Biochemical and biophysical research communications, 379(4), 882-886 (2009-01-10)
Hydroxyprolines are valuable chiral building blocks for organic synthesis of pharmaceuticals. Several microorganisms producing L-proline trans-4- and cis-3-hydroxylase were discovered and these enzymes were applied to the industrial production of trans-4- and cis-3-hydroxy-L-proline, respectively. Meanwhile, other hydroxyproline isomers, cis-4- and
Dietrich Sturm et al.
International journal of colorectal disease, 25(8), 921-929 (2010-04-21)
This study addressed the question of whether the collagen metabolism modulator cis-4-Hydroxy-L-proline (CHP) is applicable for potential use as a therapeutic inhibitor of pancreatic carcinoma cell growth. Cell proliferation, as well as quantification of apoptosis of murine Panc02 cells, was
Christoph Mueller et al.
World journal of gastroenterology, 12(10), 1569-1576 (2006-03-30)
To investigate the biological effects of cis-hydroxyproline (CHP) on the rat pancreatic carcinoma cell line DSL6A, and to examine the underlying molecular mechanisms. The effect of CHP on DSL6A cell proliferation was assessed by using BrdU incorporation. The expression of
Heather Dickens et al.
Molecular medicine reports, 1(4), 459-464 (2008-07-01)
cis-4-Hydroxy-L-proline (CHP) is being clinically evaluated as an anticancer drug. Since this compound targets the production of L-proline-rich proteins and critical L-proline residues, its impact on long-term cultures of human hepatocytes and toxicity in rats was studied to investigate possible
Sevil Oskay Halacli et al.
Clinical immunology (Orlando, Fla.), 161(2), 316-323 (2015-06-29)
Combined immunodeficiencies (CIDs) are heterogeneous group of disorders characterized by abrogated/impaired T cell development and/or functions that resulted from diverse genetic defects. In addition to the susceptibility to infections with various microorganisms, the patients may have lymphoproliferation, autoimmunity, inflammation, allergy
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.